

12

How are the variability and knowledge gaps addressed in the LLNA and current DAs – what could be done and learnt for quantifying and managing uncertainty?

de

#### **Roman LISKA**

The European Commission's science and knowledge service

Joint Research Centre



European Commission

# **Skin sensitisation – overall picture**



# Skin sensitisation – ideal world

|          | <b>Ť</b> |      | 00000000<br>00000000<br>000000000 |
|----------|----------|------|-----------------------------------|
| Chemical | Human    | LLNA | in vitro                          |
| 1        | S        | S    | NS                                |
| 2        | NS       | NS   | NS                                |
| 3        | S        | NS   | S                                 |
| 4        | S        | S    | S                                 |
|          |          |      |                                   |
| •        |          | 0    |                                   |
| n-1      | NS       | S    | NS                                |
| n        | S        | S    | NS                                |

#### **Relevance (sensitivity, specificity, accuracy)**



# **Skin sensitisation – reality**

|          | ń     |            |                        |
|----------|-------|------------|------------------------|
| Chemical | Human | LLNA       | in vitro               |
| 1        | S     | {S,S,S,NS} | {S,S,NS,NS,S,S}        |
| 2        | NS    | {NS,NS}    | {NS,NS,NS,NS,NS,NS,NS} |
| 3        | ?     | {NS}       | {S,S,NS,S,S,S}         |
| 4        | S     | {Ø}        | {S,S,S,S,S,S}          |
| •        |       |            |                        |
| n-1      | NS ?  | {S,NS,NS}  | {NS,NS,S,S,NS,S}       |
| n        | S     | {NS,NS}    | {S,S,S,NS,S,S,NS}      |

#### **Relevance and Reliability**





# Reliability

#### Within Laboratory reproducibility

#### Between Laboratory reproducibility

|      |       | LAB 1 |       |       | LAB 2 |       |       | LAB 3 |       |            |
|------|-------|-------|-------|-------|-------|-------|-------|-------|-------|------------|
|      | run 1 | run 2 | run 3 | run 1 | run 2 | run 3 | run 1 | run 2 | run 3 |            |
| TI 1 | S     | S     | S     | S     | S     | S     | S     | S     | S     |            |
| TI 2 | S     | S     | NS    | S     | S     | S     | S     | S     | NS    |            |
| TI 3 | NS    |            |
|      |       |       |       |       |       |       |       |       |       |            |
|      |       |       |       |       |       |       |       |       |       |            |
| TI N | NS    | NS    | S     | NS    | NS    | NS    | S     | NS    | NS    |            |
|      |       |       |       |       |       |       |       |       |       | concordant |
| TI 1 | D     | S     |       |       | S     |       |       | S     |       | 1          |
| TI 2 | 2     | S     |       |       | S     | ]     |       | S     |       | 1          |
| TI 3 | Ę     | NS    |       |       | NS    |       |       | NS    |       | 1          |
|      | ori.  |       |       |       |       |       |       |       |       |            |
|      | aj c  |       |       |       |       | 1     |       |       |       |            |
| TI N | Σ     | NS    |       |       | NS    |       |       | NS    |       | 1          |

95%

European Commission average

LAB



# **Skin sensitisation – reality**

|          | •        | <u>Aggregation – majority rule</u> |                                      |  |  |  |  |
|----------|----------|------------------------------------|--------------------------------------|--|--|--|--|
|          | <b>M</b> |                                    |                                      |  |  |  |  |
| Chemical | Human    | LLNA                               | in vitro                             |  |  |  |  |
| 1        | S        | {S,S,S,NS} <b>→</b>                | {S,S,NS,NS,S,S} <b>→</b>             |  |  |  |  |
| 2        | NS       | {NS,NS} → NS                       | {NS,NS,NS,NS,NS,NS,NS}               |  |  |  |  |
| 3        | ?        | {NS} → NS                          | {S,S,NS,S,S,S} → S                   |  |  |  |  |
| 4        | S        | {Ø}                                | {S,S,S,S,S,S} <b>→</b>               |  |  |  |  |
| •<br>•   |          |                                    |                                      |  |  |  |  |
| n-1      | NS ?     | {S,NS,NS}≁ NS                      | {NS,NS,S,S,NS,S} <b>→</b> ?          |  |  |  |  |
| n        | S        | {NS,NS} → NS                       | {\$,\$,\$,N\$,\$,\$,N\$} <b>&gt;</b> |  |  |  |  |

**Relevance** and Reliability





in vitro - validation study design

# Relevance

#### LAB

#### Predictive capacity

- Sensitivity
- Specificity
- Accuracy

| True classification |                      | run 1 | run 2 | run 3 | <u>m</u> | <u>najority rule</u> |                                       |
|---------------------|----------------------|-------|-------|-------|----------|----------------------|---------------------------------------|
| TN                  | TI 1                 | NS    | NS    | S     |          | NS                   |                                       |
| TN                  | TI 2                 | S     | S     | NS    |          | S                    | Specificity                           |
|                     | :                    |       |       |       |          |                      | =<br>% of negative<br>classifications |
| TN                  | $TIN_1$              | NS    | NS    | S     |          | NS                   |                                       |
| ТР                  | TI N <sub>1</sub> +1 | S     | S     | S     |          | NS                   |                                       |
| ТР                  | TI $N_1$ +2          | S     | S     | NS    |          | S                    | Sensitivity                           |
|                     | :                    |       |       |       |          |                      | =<br>% of positive<br>classifications |
| ТР                  | TI N₁+N₂             | NS    | NS    | S     |          | NS                   |                                       |



- (2) The EURL ECVAM study showed that the DPRA is transferable to suitably equipped laboratories that are proficient in high performance liquid chromatography (HPLC) analysis and the results obtained demonstrated within- and between-laboratory reproducibility of 87% and 75%, respectively.
- (3) Full evaluation of the predictive capacity and applicability domain of the DPRA were outside the scope of the EURL ECVAM study. However, based on the study results and excluding metal compounds for which the test is not applicable, the accuracy of the DPRA for distinguishing sensitisers from non-sensitisers was 82% (sensitivity of 76%, specificity of 92%) which is in agreement with published information from previous studies (Gerberick *et al.*, 2007; Bauch et al., 2012; Natsch et al., 2013).

Source: ECVAM Validation report - DPRA

(4) The Givaudan-coordinated validation study generated preliminary information on the test method's predictive capacity and it was found that the accuracy of the KeratinoSens<sup>™</sup> to discriminate skin sensitisers from non-sensitisers was 90% (sensitivity 87%, specificity 100%; n=21)<sup>1</sup>. The accuracy calculated for an additional set of chemicals (77 sensitisers and 104 non-sensitisers) tested in-house by Givaudan was 75%. These figures are similar to those recently published by Natsch et al. (2013) based on in-house testing of about 145 chemicals (77% accuracy, 79% sensitivity, 72% specificity). Taken together, this information indicates the usefulness of the KeratinoSens<sup>™</sup> assay to contribute to the identification of sensitisers and non-sensitisers.

Source: ECVAM Validation report - KeratinoSens



# **Reliability and Relevance evaluations**

- Do not capture the variability at lower levels (loss of information)
- Often based on univariate descriptive measures (not estimates)
- In context of validation
  - Not clear how to "aggregate" information for e.g. BLR evaluation
  - Do not guarantee that BLR ≤ WLR measure

#### Need for a new approach ....



#### **Important concept in statistics**



Full information, Parameters of interest can be fully known Limited information, Estimate parameters given the sample from population



10

## **Full information – example**

| True<br>classification |                      | run 1 | run 2 | run 3 |
|------------------------|----------------------|-------|-------|-------|
| TN                     | TI 1                 | 0     | 0     | 1     |
| TN                     | TI 2                 | 1     | 1     | 0     |
|                        | :                    |       | :     |       |
| TN                     | TI N <sub>1</sub>    | 0     | 0     | 1     |
| ТР                     | TI N <sub>1</sub> +1 | 1     | 1     | 1     |
| ТР                     | TI N <sub>1</sub> +2 | 1     | 1     | 0     |
|                        | :                    |       | :     |       |
| ТР                     | $TIN_1+N_2$          | 0     | 0     | 1     |



## **Alternative performance assessment**

• <u>Reproducibility measures (WLR, BLR, GR)</u>

Based on probability(m out of N chemicals have the same prediction in 3 independent runs), m=0, 1, ..., N

<u>Predictive capacity measures(Sensitivity, Specificity)</u>

Based on probability(m out of N chemicals has correctly predicted the true outcome) , m=0, 1, ..., N



### **Illustrative Example**



# **Example: h-Clat data**

|         |                 |                          | Kao                      |          |       |           |       |       |          |       |       |           |       |
|---------|-----------------|--------------------------|--------------------------|----------|-------|-----------|-------|-------|----------|-------|-------|-----------|-------|
|         |                 | Chemical                 | Reference classification | LLNA     | Ex    | cperiment | ; 1   | Ex    | periment | t 2   | Ex    | rperiment | : 3   |
|         |                 |                          |                          |          | Run 1 | Run 2     | Run 3 | Run 1 | Run 2    | Run 3 | Run 1 | Run 2     | Run 3 |
|         | 1               | Benzoquinone             | SENSITISER               | POSITIVE | P12   | P2        | P12   |       |          |       |       |           |       |
|         | 2               | PPD                      | SENSITISER               | POSITIVE | P1    | P1        | P12   |       |          |       |       |           |       |
|         | 3               | Dihydroeugenol           | SENSITISER               | POSITIVE | P12   | P12       | Ν     |       |          |       |       |           |       |
|         | 4               | Thioglycerol             | SENSITISER               | POSITIVE | P1    | P1        | P12   |       |          |       |       |           |       |
| Group 1 | 5               | Imidazolidinylurea       | SENSITISER               | POSITIVE | P12   | P12       | P12   |       |          |       |       |           |       |
|         | 6               | Methylmethacrylate       | SENSITISER               | POSITIVE | Ν     | Ν         | Ν     |       |          |       |       |           |       |
|         | 7               | Glycerol                 | NON SENSITISER           | NEGATIVE | Ν     | Ν         | Ν     |       |          |       |       |           |       |
|         | 8               | 2,4-Dichloronitrobenzene | NON SENSITISER           | NEGATIVE | P12   | P12       | P12   |       |          |       |       |           |       |
|         | 9               | Benzyl alcohol           | NON SENSITISER           | NEGATIVE | P1    | Ν         | P1    |       |          |       |       |           |       |
|         | 10              | Kathon CG (CMI/MI)       | SENSITISER               | POSITIVE | P2    | P12       | P2    | P2    | P2       | P1    | P1    | P12       | P2    |
|         | 11              | Beryllium sulfate        | SENSITISER               | POSITIVE | Ν     | Ν         | Ν     | Ν     | Ν        | Ν     | Ν     | Ν         | Ν     |
|         | 12              | Formaldehyde             | SENSITISER               | POSITIVE | P12   | P12       | P12   | P12   | P12      | P12   | P1    | P1        | P12   |
|         | 13              | Chloramine T             | SENSITISER               | POSITIVE | P12   | P2        | P12   | P2    | P12      | P12   | P12   | P2        | P2    |
|         | 14              | Chlorpromazine HCl       | SENSITISER               | POSITIVE | P12   | P12       | P12   | P2    | P2       | P2    | P2    | P1        | P12   |
|         | 15              | 2-Mercaptobenzothiazole  | SENSITISER               | POSITIVE | P2    | P2        | P2    | P2    | P2       | P2    | P12   | P2        | P2    |
|         | 16              | Benzyl salicylate        | SENSITISER               | POSITIVE | Ν     | Ν         | Ν     | P2    | P2       | Ν     | Ν     | P2        | Ν     |
| Group 2 | 17              | Benzyl cinnamate         | SENSITISER               | POSITIVE | Ν     | Ν         | Ν     | Ν     | Ν        | Ν     | Ν     | Ν         | Ν     |
|         | 18              | R(+)- Limonene           | SENSITISER               | POSITIVE | P12   | P12       | P2    | P12   | P2       | P12   | P2    | P2        | P2    |
|         | 19              | Methyl salicylate        | NON SENSITISER           | NEGATIVE | P1    | P1        | Ν     | Ν     | Ν        | Ν     | Ν     | P2        | P12   |
|         | 20              | Isopropanol              | NON SENSITISER           | NEGATIVE | Ν     | Ν         | Ν     | Ν     | Ν        | Ν     | Ν     | Ν         | Ν     |
|         | 21              | Dimethyl isophtalate     | NON SENSITISER           | NEGATIVE | Ν     | P2        | Ν     | Ν     | Ν        | Ν     | Ν     | P2        | Ν     |
|         | 22              | 4-Aminobenzoic acid      | NON SENSITISER           | NEGATIVE | N     | Ν         | Ν     | P12   | Ν        | Ν     | Ν     | Ν         | Ν     |
|         | $\overline{23}$ | Nickel chloride          | SENSITISER               | NEGATIVE | P12   | P12       | P12   | P12   | P2       | P12   | P12   | P12       | P12   |
|         | 24              | Xylene                   | NON SENSITISER           | POSITIVE | Ν     | P2        | Ν     | Ν     | Ν        | Ν     | Ν     | Ν         | Ν     |



#### **Example: h-Clat**

#### one test item



Commission

#### **Example: h-Clat data**

| HUMAN | Test item # | S  | NS |
|-------|-------------|----|----|
| 1     | 1           | 5  | 7  |
| 1     | 2           | 11 | 1  |
| 1     | 3           | 4  | 0  |
| 1     | 4           | 4  | 0  |
| 1     | 5           | 11 | 1  |
| 1     | 6           | 12 | 0  |
| 1     | 7           | 10 | 2  |
| 1     | 8           | 12 | 0  |
| 1     | 9           | 5  | 7  |
| 1     | 10          | 4  | 0  |
| 1     | 11          | 4  | 0  |
| 1     | 12          | 12 | 0  |
| 1     | 13          | 4  | 8  |
| 1     | 14          | 4  | 0  |
| 1     | 15          | 12 | 0  |
| 1     | 16          | 0  | 4  |
| 0     | 17          | 0  | 4  |
| 0     | 18          | 4  | 0  |
| 0     | 19          | 4  | 0  |
| 0     | 20          | 6  | 6  |
| 0     | 21          | 0  | 12 |
| 0     | 22          | 1  | 11 |
| 0     | 23          | 0  | 12 |
| 0     | 24          | 4  | 8  |

#### **Example: h-Clat**

|                                 | average | Kao            | Shiseido       | Bioassay       | EURL ECVAM     |
|---------------------------------|---------|----------------|----------------|----------------|----------------|
| h-CLAT report $WLR$             | 80.0%   | 86.7%          | 80.0%          | 73.3%          | 80.0%          |
| $WLR_0$                         | 84.8%   | 88.6%          | 82.4%          | 85.5%          | 82.7%          |
| $\widehat{WLR}_1$               | 83.5%   | 88.2%          | 81.4%          | 81.6%          | 82.9%          |
| $\widehat{WLR}_{1BC}$           | 82.4%   | 88.0%          | 79.2%          | 81.4%          | 80.8%          |
| $95\%$ bootstrap CI for $WLR_1$ |         | (82.1%, 94.1%) | (71.4%, 87.6%) | (74.1%, 89.4%) | (74.4%, 87.6%) |

(a) WLR estimates

|                              |         | Kao            | Kao            | Kao            | Shiseido       |
|------------------------------|---------|----------------|----------------|----------------|----------------|
|                              |         | Shiseido       | Shiseido       | Bioassay       | Bioassay       |
|                              | average | Bioassay       | EURL ECVAM     | EURL ECVAM     | EURL ECVAM     |
| h-CLAT report $BLR$          | 82.3%   | 87.5%          | 79.2%          | 83.3%          | 79.2%          |
| $BLR_0$                      | 82.4%   | 91.1%          | 78.4%          | 81.7%          | 78.4%          |
| $\widehat{BLR}_1$            | 75.2%   | 81.1%          | 71.5%          | 75.8%          | 72.4%          |
| $\widehat{BLR}_{1BC}$        | 76.9%   | 84.0%          | 73.1%          | 77.1%          | 73.6%          |
| 95% bootstrap CI for $BLR_1$ |         | (78.8%, 89.2%) | (68.4%, 78.0%) | (72.2%, 82.7%) | (68.8%, 78.9%) |

(b) BLR estimates

Table 1: h-CLAT. WLR and BLR estimates and its 95% confidence intervals(CI). Notation:  $\widehat{WLR}_{1BC}$  is the bootstrap corrected estimate of  $WLR_1$ .(similarly for  $\widehat{BLR}_{1BC}$ )



# **Example: h-Clat**

Probability(SENSITISER)

|         |                          | $\hat{q}(c) = \text{est. P(chemical } c \text{ is classified as P)}$ |      |          |          |       |
|---------|--------------------------|--|------|----------|----------|-------|
|         | Chemical                 | Reference classification   | Kao  | Shiseido | Bioassay | ECVAM |
| Group 1 |                          |  |      |          |          |       |
| 1       | Benzoquinone             | SENSITISER   | 1    | 1        | 1        | 1     |
| 2       | PPD                      | SENSITISER   | 1    | 1        | 1        | 1     |
| 3       | Dihydroeugenol           | SENSITISER   | 0.74 | 0.74     | 1        | 1     |
| 4       | Thioglycerol             | SENSITISER   | 1    | 1        | 1        | 0.74  |
| 5       | Imidazolidinylurea       | SENSITISER   | 1    | 1        | 1        | 1     |
| 6       | Methylmethacrylate       | SENSITISER   | 0    | 0        | 0        | 0     |
| 7       | Glycerol                 | NON SENSITISER   | 0    | 0        | 0        | 0     |
| 8       | 2,4-Dichloronitrobenzene | NON SENSITISER   | 1    | 1        | 1        | 1     |
| 9       | Benzyl alcohol           | NON SENSITISER   | 0.74 | 0.74     | 1        | 1     |
| Group 2 |                          |  |      |          |          |       |
| 10      | Kathon CG (CMI/MI)       | SENSITISER   | 1    | 0.92     | 0.97     | 0.97  |
| 11      | Beryllium sulfate        | SENSITISER   |      | 0.58     | 0.03     | 0.79  |
| 12      | Formaldehyde             | SENSITISER   | 1    | 0.87     | 0.87     | 1     |
| 13      | Chloramine T             | SENSITISER   | 1    | 0.94     | 1        | 1     |
| 14      | Chlorpromazine HCl       | SENSITISER   | 1    | 1        | 0.97     | 0.87  |
| 15      | 2-Mercaptobenzothiazole  | SENSITISER   | 1    | 1        | 1        | 1     |
| 16      | Benzyl salicylate        | SENSITISER   | 0.26 | 0.13     | 0.16     | 1     |
| 17      | Benzyl cinnamate         | SENSITISER   |      | 0.79     | 0        | 0.42  |
| 18      | R(+)- Limonene           | SENSITISER   | 1    | 1        |          | 1     |
| 19      | Methyl salicylate        | NON SENSITISER   | 0.33 | 0.13     | 0.25     | 0.97  |
| 20      | Isopropanol              | NON SENSITISER   | 0    | 0.03     | 0.03     | 0     |
| 21      | Dimethyl isophtalate     | NON SENSITISER   | 0.13 | 0        | 0.13     | 0.39  |
| 22      | 4-Aminobenzoic acid      | NON SENSITISER   | 0.03 | 0        | 0        | 0.03  |
| 23      | Nickel chloride          | SENSITISER   | 1    | 1        | 1        | 1     |
| 24      | Xylene                   | NON SENSITISER   | 0.03 | 0.03     | 0.42     | 1     |



## **Example: DA skin sensitisation**

#### Performance measures based on 100.000 Bootstrap replicates

|              |                 |          | vs. LLNA    |             |
|--------------|-----------------|----------|-------------|-------------|
|              | reproducibility | accuracy | specificity | sensitivity |
| DPRA         | 79.3%           | 75.0%    | 86.1%       | 69.5%       |
| KeratinoSens | 90.2%           | 69.1%    | 65.6%       | 70.8%       |
| hClat        | 80.6%           | 69.1%    | 55.2%       | 76.1%       |
| 2of3         | 85.6%           | 72.9%    | 67.3%       | 75.8%       |
| STS          | 83.6%           | 75.6%    | 52.4%       | 87.2%       |







|              | specificity   |                 |  |  |
|--------------|---------------|-----------------|--|--|
|              | majority rule | bootstrap based |  |  |
| DPRA         | 100.0%        | 86.1%           |  |  |
| KeratinoSens | 62.5%         | 65.6%           |  |  |
| hClat        | 50.0%         | 55.2%           |  |  |
| 2of3         | 75.0%         | 67.3%           |  |  |
| STS          | 57.1%         | 52.4%           |  |  |

|              | sensitivity   |                 |  |  |
|--------------|---------------|-----------------|--|--|
|              | majority rule | bootstrap based |  |  |
| DPRA         | 62.5%         | 69.5%           |  |  |
| KeratinoSens | 68.8%         | 70.8%           |  |  |
| hClat        | 68.8%         | 76.1%           |  |  |
| 2of3         | 68.8%         | 75.8%           |  |  |
| STS          | 75.0%         | 87.2%           |  |  |



## Summary

#### Need for better performance evaluations

- To compare methods and/or DA
- Data variability characterization
- Expert judgement plays still an important role
- A possible way based on probability measures
- Some issues to be resolved
  - Unbalanced data
  - Missing data (Bayesian approach?)
  - Complexity
- Purpose/use of a method decision making



# **Stay in touch**



EU Science Hub: ec.europa.eu/jrc



Twitter: @EU\_ScienceHub



Facebook: EU Science Hub - Joint Research Centre



LinkedIn: Joint Research Centre



YouTube: EU Science Hub



# The Joint Research Centre at a glance

#### 3000 staff

Almost 75% are scientists and researchers. Headquarters in Brussels and research facilities located in 5 Member States.



## **Example: DA skin sensitisation**

#### majority rule of predictions

|              | vs. LLNA |             |             |  |  |
|--------------|----------|-------------|-------------|--|--|
|              | accuracy | specificity | sensitivity |  |  |
| DPRA         | 75.0%    | 100.0%      | 62.5%       |  |  |
| KeratinoSens | 66.7%    | 62.5%       | 68.8%       |  |  |
| hClat        | 62.5%    | 50.0%       | 68.8%       |  |  |
| 2of3         | 70.8%    | 75.0%       | 68.8%       |  |  |
| STS          | 72.0%    | 57.1%       | 75.0%       |  |  |

#### Performance measures based on 100.000 Bootstrap replicates

|              |                 |          | vs. LLNA    |             |
|--------------|-----------------|----------|-------------|-------------|
|              | reproducibility | accuracy | specificity | sensitivity |
| DPRA         | 79.3%           | 75.0%    | 86.1%       | 69.5%       |
| KeratinoSens | 90.2%           | 69.1%    | 65.6%       | 70.8%       |
| hClat        | 80.6%           | 69.1%    | 55.2%       | 76.1%       |
| 2of3         | 85.6%           | 72.9%    | 67.3%       | 75.8%       |
| STS          | 83.6%           | 75.6%    | 52.4%       | 87.2%       |



